Opinion: NIH: It’s time to make your mark on the renaissance of medicinal psychedelics

Just a few years ago, investments in medicinal psychedelic research were rare in even the riskiest of financial portfolios. But with entrepreneurs and financiers now pouring money into developing psychedelic treatments for mental and behavioral health issues, it’s clear that investors, like many scientists, envision a psychedelic path for psychiatry. There’s a notable holdout though: the National Institutes of Health, the world’s largest public funder of medical research.

The NIH’s absence from investment in psychedelic medicine is unfortunate, since it is preventing talented researchers from entering the field and possibly slowing the development of urgently needed innovative treatments.

Read the rest…

Opinion: NIH: It’s time to make your mark on the renaissance of medicinal psychedelics

Leave a Reply

Your email address will not be published. Required fields are marked *

Scroll to top